Academic Journal
Frequency of SARS-CoV-2 RNA Detection in Foreign Medical Students Vaccined against New Coronavirus Infection ; Частота выявления РНК SARS-CoV-2 у иностранных студентов медицинского вуза, привитых против новой коронавирусной инфекции
| العنوان: | Frequency of SARS-CoV-2 RNA Detection in Foreign Medical Students Vaccined against New Coronavirus Infection ; Частота выявления РНК SARS-CoV-2 у иностранных студентов медицинского вуза, привитых против новой коронавирусной инфекции |
|---|---|
| المؤلفون: | O. A. Ryabtseva, P. V. Tsygankov, S. V. Shlyk, G. G. Kharseeva, A. V. Chepusova, О. А. Рябцева, П. В. Цыганков, С. В. Шлык, Г. Г. Харсеева, А. В. Чепусова |
| المصدر: | Epidemiology and Vaccinal Prevention; Том 22, № 1 (2023); 82-88 ; Эпидемиология и Вакцинопрофилактика; Том 22, № 1 (2023); 82-88 ; 2619-0494 ; 2073-3046 |
| بيانات النشر: | «Numicom» LLC |
| سنة النشر: | 2023 |
| المجموعة: | Epidemiology and Vaccine Prevention (E-Journal) / Эпидемиология и Вакцинопрофилактика |
| مصطلحات موضوعية: | новая коронавирусная инфекция, PCR, vaccines, novel coronavirus infection, ПЦР, вакцины |
| الوصف: | Relevance. The incidence of the novel coronavirus infection is on the rise worldwide. To effectively combat COVID-19, both vaccination and control of the circulation of SARS-CoV-2 strains among the population and, especially, foreign citizens arriving in Russia from around the world are necessary. Aim. To determine the frequency of detection of SARS-CoV-2 RNA in foreign medical students vaccinated against COVID-19 with various vaccine preparations. Materials and methods. Foreign students (510 people) of a medical university aged 18-25 years, vaccinated against COVID-19, who arrived in Russia during June-August 2021, were examined. The determination of SARS-CoV-2 RNA was carried out weekly from December 2021 to January 2022 by taking smears from the oropharynx and examining them using a test-PCR systems manufactured by the Federal State Budgetary Institution of the Central Research Institute of Epidemiology of Rospotrebnadzor «AmplisensCov-Bat-FL» (registration certificate No. RZN 2014/1987 dated 07.04.2020). Results. SARS-CoV-2 RNA was detected in 41 (8.0% [95% CI 5.6÷10.4]) of 510 international students surveyed. Among those vaccinated with vector vaccines based on human adenovirus (Sputnik V, Sputnik Light, Ad26. COV2.S (Johnson&Johnson)) SARS-CoV-2 RNA was detected in 27 (7.6% [95% CI 4.8÷10.4]) a person, mainly after 4–6 months. after vaccination; vaccines based on modified mRNA (BNT162b2 (Pfizer/BioNTech), mRNA1273 (Moderna)) – 5.7% [95% CI 1.1÷10.3] people within six months after vaccination. The infectious process was asymptomatic in 39 people, in two (vaccinated with the BNT162b2 vaccine (Pfizer / BioNTech) and Sputnik Light) it had clinical manifestations of severe and moderate severity. Conclusion. Among foreign students vaccinated against COVID-19, in addition to two cases, asymptomatic carriers of SARS-CoV-2 have been identified, which may be a potential source of infection. This indicates the need for vaccination and timely revaccination of foreign and Russian students, as well as compliance ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| Relation: | https://www.epidemvac.ru/jour/article/view/1744/910; Никифоров В. В., Суранова Т. Г., Миронов А. Ю. Новая коронавирусная инфекция (COVID-19): этиология, эпидемиология, клиника, диагностика, лечение и профилактика: учебно-методическое пособие. М.: Издательство Академия постдипломного образования ФМБА; 2020.; Micah A.E., Cogswell I.E., Cunningham B., et al. Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050. The lancet. 2021. Vol. 398, N10308. P.1317–1343. doi:10.1016/S0140-6736(21)01258-7; Ibrahim M., Areej N., Pradipta P., et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum. Vaccin. Immunother. 2022. Vol. 3. P.1–20. doi:10.1080/21645515.2022.2027160; Araf Y., Akter F., Tang Y.D., et al. Omicron variant of SARS‐CoV‐2: Genomics, transmissibility, and responses to current COVID‐19 vaccines //J. Med.Virol. 2022. P.1–8. doi:10.1002/jmv.27588; Brentville V.A., Vankemmelbeke M., Metheringham R.L., et al. A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants. bioRxiv. 2021. Vol.6, N18. P. 448932. doi:10.1101/2021.06.18.448932; Кузьмина Л.П., Шиган Е.Е., Брико Н.И. и др. Новая коронавирусная инфекция COVID-19: профессиональные аспекты сохранения здоровья и безопасности медицинских работников: методические рекомендации (2-е издание, переработанное и дополненное). М.: АМТ, ФГБНУ «НИИ МТ», 2022.; Abdulla Z.A., Al‐Bashir S.M., Al‐Salih N.S., et sl. A Summary of the SARS‐CoV‐2 Vaccines and Technologies Available or under Development. Pathogen. 2021. Vol.10, N7. P.788. doi:10.3390/pathogens10070788; Noh J.Y., Jeong H.W., Shin EC. SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern. Sig. Transduct. Target. Ther. 2021. Vol. 6. P.203.doi:10.1038/s41392-021-00623-2; Харченко Е. П. Вакцины против Covid-19: сравнения, ограничения, спад пандемии и перспектива ОРВИ. Эпидемиология и Вакцинопрофилактика. 2021;20(1):4– 19. doi:10.31631/2073-3046-2021-20-1-4-19; Vitiello A., Ferrara F., Troiano V., et al. COVID-19 vaccines and decreased transmission of SARS-CoV-2 .Inflammopharmacol. 2021. Vol. 29. P.1357–1360. doi:10.1007/s10787-021-00847-2; Приказ Минздрава России №1122н от 06.12.2021 г. «Об утверждении национального календаря профилактических прививок, календаря профилактических прививок по эпидемическим показаниям и порядка проведения профилактических прививок». - Москва, 2021. – 15 с.; Kudlay D., Svistunov A. COVID-19 Vaccines: An Overview of Different Platforms. Bioengineering.2022. Vol. 9, N2. P.72. doi:10.3390/bioengineering9020072; Geers D., Shamier M.C., Bogers S., et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccines. SciImmunol. 2021. Vol. 6, N59. P.1750. doi:10.1126/sciimmunol.abj1750; Chang X., Augusto G.S., Liu X., et al. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. Allergy. 2021.Vol. 76, N 9. P. 2895–2998. doi:10.1111/all.14893; Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021. Vol.595, N7865. P.17–18. doi:10.1038/d41586-021-01696-3; Ikegame S., Siddiquey M.N.A., Hung C.T., et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat. Commun. 2021. Vol. 12, N 1. P. 4598. doi:10.1038/s41467-021-24909-9; Knoll M.D., Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021. Vol. 397, N 10269. P. 72–74. doi:10.1016/S0140-6736(20)32623-4; Polack F.P., Thomas S.J., Kitchin N., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020. Vol. 383, N27. P.2603–2615. doi:10.1056/NEJMoa2034577; https://www.epidemvac.ru/jour/article/view/1744 |
| DOI: | 10.31631/2073-3046-2023-22-1-82-88 |
| الاتاحة: | https://www.epidemvac.ru/jour/article/view/1744 https://doi.org/10.31631/2073-3046-2023-22-1-82-88 |
| Rights: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant to the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующиеся в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.9F8B8F2 |
| قاعدة البيانات: | BASE |
| DOI: | 10.31631/2073-3046-2023-22-1-82-88 |
|---|